Early treatment in multiple sclerosis

Journal of the Neurological Sciences

Volumn 311, Issue SUPPL. 1, 2011, Pages

  Elovaara, Irina ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

CIS; Early treatment; Glatiramer acetate; Interferon beta; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ARTICLE; CLINICAL PRACTICE; FOLLOW UP; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EARLY MEDICAL INTERVENTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; PROGNOSIS; RISK FACTORS;

EID: 84855252402     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/S0022-510X(11)70005-3     Document Type: Article

References (40)

1. WI McDonald, A Compston, G Edan, D Goodkin, HP Hartung, FD Lublin et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis Ann Neurol 50 2001 121 127
2. CM Dalton, PA Brex, KA Miszkiel, SJ Hickman, DG MacManus, GT Plant et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis Ann Neurol 52 2002 47 53 (Pubitemid 34693742)
3. M Tintoré, A Rovira, J Rio, C Nos, E Grive, J Sastre-Garriga et al. New diagnostic criteria for multiple sclerosis: application in first demyelinating episode Neurology 60 2003 27 30 (Pubitemid 36070639)
4. X Montalban, M Tintore, J Swanton, F Barkhof, F Fazekas, M Filippi et al. MRI criteria for MS in patients with clinically isolated syndromes Neurology 74 2010 427 434
5. T Kuhlmann, G Lingfeld, A Bitsch, J Schuchardt, W Bruck Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time Brain 125 2002 2202 2212
6. A Compston, A Coles Multiple sclerosis Lancet 372 2008 1502 1517
7. A Bitsch, J Schuchardt, S Bunkowski, T Kuhlmann, W Bruck Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation Brain 123 Pt 6 2000 1174 1183 (Pubitemid 30312109)
8. BD Trapp, J Peterson, RM Ransohoff, R Rudick, S Mork, L Bo Axonal transection in the lesions of multiple sclerosis N Engl J Med 338 1998 278 285 (Pubitemid 28065253)
9. B Audoin, D Ibarrola, I Malikova, E Soulier, S Confort-Gouny, MV Duong et al. Onset and underpinnings of white matter atrophy at the very early stage of multiple sclerosis-a two-year longitudinal MRI/MRSI study of corpus callosum Mult Scler 13 2007 41 51 (Pubitemid 46152760)
10. B Audoin, W Zaaraoui, F Reuter, A Rico, I Malikova, S Confort-Gouny et al. Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis J Neurol Neurosurg Psychiatry 81 2010 690 695
11. PA Brex, R Jenkins, NC Fox, WR Crum, JI O'Riordan, GT Plant et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS Neurology 54 2000 1689 1691 (Pubitemid 30226819)
12. CM Dalton, PA Brex, R Jenkins, NC Fox, KA Miszkiel, WR Crum et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis J Neurol Neurosurg Psychiatry 73 2002 141 147
13. M Di Filippo, VM Anderson, DR Altmann, JK Swanton, GT Plant, AJ Thompson et al. Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes J Neurol Neurosurg Psychiatry 81 2010 204 208
14. N De Stefano, A Giorgio, M Battaglini, M Rovaris, MP Sormani, F Barkhof et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes Neurology 74 2010 1868 1876
15. BG Weinshenker, B Bass, GP Rice, J Noseworthy, W Carriere, J Baskerville et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability Brain 112 Pt 1 1989 133 146 (Pubitemid 19056478)
16. BG Weinshenker, B Bass, GP Rice, J Noseworthy, W Carriere, J Baskerville et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course Brain 112 Pt 6 1989 1419 1428 (Pubitemid 20024212)
17. LK Fisniku, PA Brex, DR Altmann, KA Miszkiel, CE Benton, R Lanyon et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis Brain 131 2008 808 817 (Pubitemid 351294716)
18. M Tintore, A Rovira, J Rio, C Nos, E Grive, N Tellez et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes Neurology 67 2006 968 972 (Pubitemid 44454586)
19. C Polman, L Kappos, MS Freedman, G Edan, HP Hartung, DH Miller et al. Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b J Neurol 255 2008 480 487
20. JM Nielsen, C Pohl, CH Polman, F Barkhof, MS Freedman, G Edan et al. MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome BMC Neurol 9 2009 19
21. C Confavreux, S Vukusic, P Adeleine Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process Brain 126 2003 770 782 (Pubitemid 36372978)
22. A Langer-Gould, RA Popat, SM Huang, K Cobb, P Fontoura, MK Gould et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review Arch Neurol 63 2006 1686 1691 (Pubitemid 44925075)
23. BG Weinshenker, GP Rice, JH Noseworthy, W Carriere, J Baskerville, GC Ebers The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome Brain 114 Pt 2 1991 1045 1056
24. LD Jacobs, RW Beck, JH Simon, RP Kinkel, CM Brownscheidle, TJ Murray et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group N Engl J Med 343 2000 898 904
25. G Comi, M Filippi, F Barkhof, L Durelli, G Edan, O Fernandez et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study Lancet 357 2001 1576 1582 (Pubitemid 32488815)
26. L Kappos, CH Polman, MS Freedman, G Edan, HP Hartung, DH Miller et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurology 67 2006 1242 1249 (Pubitemid 44563835)
27. G Comi, V Martinelli, M Rodegher, L Moiola, O Bajenaru, A Carra et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial Lancet 374 2009 1503 1511
28. G Comi Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta Clin Ther 31 2009 1142 1157
29. SL Galetta The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study) J Neuroophthalmol 21 2001 292 295 (Pubitemid 34027532)
30. D Arnold, S Narayanan, S Antel Treatment with glatiramer acetate protects axons in patients with clinically isolated syndromes: evidence from the PreCISe trial Mult Scler 14 2008 S10
31. DL Arnold, N De Stefano, S Narayanan, PM Matthews Proton MR spectroscopy in multiple sclerosis Neuroimaging Clin N Am 10 2000 789 798 ix-x. (Pubitemid 32391268)
32. M Filippi, MA Rocca, E Perego, F Agosta, A Meani, O Bajenaru et al. Benefit of early treatment with glatiramer acetate: MRI results from the 5-year prospectively planned follow up in patients with clinically isolated syndrome enrolled in the PreCISe study Mult Scler 16 2010 S349
33. L Kappos, MS Freedman, CH Polman, G Edan, HP Hartung, DH Miller et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study Lancet 370 2007 389 397 (Pubitemid 47189673)
34. L Kappos, MS Freedman, CH Polman, G Edan, HP Hartung, DH Miller et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial Lancet Neurol 8 2009 987 997
35. RP Kinkel, C Kollman, P O'Connor, TJ Murray, J Simon, D Arnold et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event Neurology 66 2006 678 684 (Pubitemid 43739821)
36. RP Kinkel, M Dontchev, JP Tanner, C Kollman, J Simon, PW O'Connor et al. CHAMPIONS: 10-year follow-up after a clinically isolated syndrome in patients at high risk for developing multiple sclerosis Multiple Sclerosis 15 2009 P466
37. European Medicines Agency. Refusal of the marketing authorisation for Movectro (cladribine) 2010 [cited; Available from: http://www.ema.europa.eu/ docs/en-GB/document-library/Summary-of-opinion---Initial-authorisation/human/ 001197/WC500097016.pdf
38. P O'Connor, RP Kinkel, M Kremenchutzky Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria Mult Scler 15 2009 728 734
39. BM Uitdehaag, L Kappos, L Bauer, MS Freedman, D Miller, R Sandbrink et al. Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization Mult Scler 11 2005 227 231 (Pubitemid 40403264)
40. I Elovaara, S Atula, JP Erälinna, M Färkkilä, T Pirttilä, A Remes et al. [Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis] Duodecim 126 2010 199 200